Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

Human Gene Therapy

Volumn 10, Issue 8, 1999, Pages 1261-1268

  Palmer, K ^a   Moore, J ^b   Everard, M ^a   Harris, J D ^a   Rodgers, S ^c   Rees, R C ^d   Murray, A K ^c   Mascari, R ^e   Kirkwood, J ^e   Riches, P G ^f   Fisher, C ^b   Thomas, J M ^b   Harries, M ^a   Johnston, S R D ^b   Collins, M K L ^a,g   Gore, M E ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g Windeyer Building ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FEMALE; FEVER; GENE THERAPY; HEADACHE; HUMAN; MALE; MELANOMA; METASTASIS; RETROVIRUS; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; VIRUS RECOMBINANT;

ADULT; CANCER VACCINES; CELL TRANSPLANTATION; FEMALE; GENE THERAPY; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VACCINATION; VACCINES, DNA;

UNIDENTIFIED RETROVIRUS;

EID: 0033587173     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017941     Document Type: Article

References (26)

1. ABDEL-WAHAB, Z., WELTZ, C., HESTER, D., PICKETT, N., VERVAERT, C., BARBER, J.R., JOLLY, D., and SEIGLER, H.F. (1997). A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80, 401-412.
2. ARIENTI, F., SULE-SUSO, J., BELLI, F., MASCHERONI, L., RIVOLTINI, L., MELANI, C., MAIO, M., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1996). Limited antitumor T cell response in melanoma patients vaccinated with IL-2 gene-transduced allogeneic melanoma cells. Hum. Gene. Ther. 7, 1955-1963.
3. ASHER, A.L., MULE, J.J., KASID, A., RESTIFO, N.P., SALO, J.C., REICHERT, C.M., JAFFE, G., FENDLY, B., KRIEGLER, M., and ROSENBERG, S.A. (1991). Murine tumour cells transduced with the gene for TNF-α. Evidence for paracrine immune effects of TNF against tumours. J. Immunol. 146, 3227-3234.
4. BERD, D., MAGUIRE, H.C., JR., SCHUCHTER, L.M., HAMILTON, R., HAUCK, W.W., SATO, T., and MASTRANGELO, M.J. (1997). Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359-2370.
5. BRIDGEWATER, J.A., and GORE, M.E. (1995). Biological response modifiers in melanoma. Br. Med. Bull. 51, 656-677.
6. COULIE, P.G. (1997). Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines? Mol. Med. Today 3, 261-268.
7. DANOS, O., and MULLIGAN, R.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85, 6460-6464.
8. DE WIT, D., FLEMMING, C.L., HARRIS, J.D., PALMER, K.J., MOORE, J.S., GORE, M.E., and COLLINS, M.K. (1996). IL-12 stimulation but not B7 expression increases melanoma killing by patient CTL. Clin. Exp. Immunol. 105, 353-359.
9. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
10. ELLEM, K.A., O'ROURKE, M.G., JOHNSON, G.R., PARRY, G., MISKO, I.S., SCHMIDT, C.W., PARSONS, P.G., BURROWS, S.R., CROSS, S., FELL, A., LI, C.L., BELL, J.R., DUBOIS, P.J., MOSS, D.J., GOOD, M.F., KELSO, A., COHEN, L.K., DRANOFF, G., and MULLIGAN, R.C. (1997). A case report: Immune responses and clinical course of the first human use of GMCSF-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 44, 10-20.
11. ELLIOTT, G.T., MCLEOD, R.A., PEREZ, J., and VON ESCHEN, K.B. (1993). Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9, 264-272.
12. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). IL-2 production by tumour cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
13. GANSBACHER, B., BANNERJI, R., DANIELS, B., ZIER, K., CRONIN, K., and GILBOA, E. (1990a). Retroviral vector-mediated γ-IFN gene transfer into tumour cells generates potent and long lasting antitumour immunity. Cancer Res. 50, 7820-7825.
14. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990b). IL-2 gene transfer abrogates tumourigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
15. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumour cells engineered to secrete IL-4. Science 254, 713-716.
16. JAGER, E., RINGHOFFER, M., ALTMANNSBERGER, M., ARAND, M., KARBACH, J., JAGER, D., OESCH, F., and KNUTH, A. (1997). Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142-147.
17. KIRKWOOD, J.M., STRAWDERMAN, M.H., ERNSTOFF, M.S., SMITH, T.J., BORDEN, E.C., and BLUM, R.H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17.
18. LIVINGSTON, P.O., WONG, G.Y., ADLURI, S., TAO, Y., PADAVAN, M., PARENTE, R., HANLON, C., CALVES, M.J., HELLING, F., and RITTER, G. (1994). Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036-1044.
19. MCGEE, J.M., LYTLE, G.H., MALNAR, K.F., PRICE, J.A., and HUMPHREY, L.J. (1991). Melanoma tumour vaccine: Five-year follow-up. J. Surg. Oncol. 47, 233-238.
20. MITCHELL, M.S., HAREL, W., KAN-MITCHELL, J., LEMAY, L.G., GOEDEGEBUURE, P., HUANG, X.Q., HOFMAN, F., and GROSHEN, S. (1993). Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann. N.Y. Acad. Sci. 690, 153-166.
21. MORTON, D.L., FOSHAG, L.J., HOON, D.S., NIZZE, J.A., FAMATIGA, E., WANEK, L.A., CHANG, C., DAVTYAN, D.G., GUPTA, R.K., and ELASHOFF, R. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463-482.
22. MULCAHY, K.A., RIMOLDI, D., BRASSEUR, F., RODGERS, S., LIENARD, D., MARCHAND, M., RENNIE, I.G., MURRAY, A.K., MCINTYRE, C.A., PLATTS, K.E., LEYVRAZ, S., BOON, T., and REES, R.C. (1996). Infrequent expression of the MAGE gene family in uveal melanomas. Int. J. Cancer 66, 738-742.
23. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
24. PATEL, P.M., FLEMMING, C.L., FISHER, C., PORTER, C.D., THOMAS, J.M., GORE, M.E., and COLLINS, M.K. (1994). Generation of IL-2-secreting melanoma cell populations from resected metastatic tumours. Hum. Gene Ther. 5, 577-584.
25. VEELKEN, H., MACKENSEN, A., LAHN, M., KOHLER, G., BECKER, D., FRANKE, B., BRENNSCHEIDT, U., KULMBURG, P., ROSENTHAL, F.M., KELLER, H., HASSE, J., SCHULTZE-SEEMANN, W., FARTHMANN, E.H., MERTELSMANN, R., and LINDEMANN, A. (1997). A phase I clinical study of autologous tumour cells plus IL-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 70, 269-277.
26. WALLACK, M.K., SIVANANDHAM, M., BALCH, C.M., URIST, M.M., BLAND, K.I., MURRAY, D., ROBINSON, W.A., FLAHERTY, L.E., RICHARDS, J.M., and BARTOLUCCI, A.A. (1995). A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75, 34-42.